POST Online Media Lite Edition


Joseph C. Papa to be chairman and CEO of Valeant

Staff writer |
Laval, QC, Canada - Valeant Pharmaceuticals International, Inc. announced that it has named Joseph C. Papa to become Valeant's chairman and chief executive officer.

Mr. Papa is expected to join Valeant by early May. Mr. Papa will join Valeant from Perrigo Company plc, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer.

Mr. Papa has more than 35 years of experience in the pharmaceutical, healthcare services and specialty pharmaceutical industries, including 20 years of branded prescription drug experience. Mr. Papa has been CEO of Perrigo since 2006 and was appointed as Chairman of the Board of Directors of Perrigo in 2007.

Prior to Perrigo, Mr. Papa served from December 2004 to October 2006 as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc.

From 2001 to 2004, he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. While at Novartis and Pharmacia /Searle, he was responsible for overseeing the successful launches of Diovan, Celebrex and Lotrel.


Pershimex Resources appoints Serge M. Racine to board
DAVIDsTEA appoints Frank Zitella as chief financial officer
DAVIDsTEA apoints two to board
CN appoints Jean-Jacques Ruest as president, CEO and director
Acasti Pharma appoints Donald Olds to board

What to read next

Valeant to sell Sprout subsidiary to former shareholders of Sprout
Valeant earned $1.05 per share in Q2
Valeant to trim debt pile with $930 million iNova sale